Glargine as a Basal Insulin Supplement in Recovering Critically Ill Patients – An In Silico Study

Normy N. Razak ∗ Jessica Lin ∗∗ J. Geoffrey Chase ∗ Geoffrey M. Shaw ∗∗∗ Christopher G. Pretty ∗ Aaron Le Compte ∗ Fatanah M. Suhaimi ∗ Ummu Jamaludin ∗

∗ Center for Bioengineering, University of Canterbury, New Zealand
∗∗ Department of Medicine, University of Otago Christchurch, New Zealand
∗∗∗ Department of Intensive Care Medicine, Christchurch Hospital, New Zealand

Abstract: Tight glycaemic control is now benefiting medical and surgical intensive care patients by reducing complications associated with hyperglycaemia. Once patients leave this intensive care environment, less acute wards do not continue to provide the same level of glycaemic control. Main reason is that these less acute wards do not have the high levels of nursing resources to provide the same level of glycaemic control. Therefore developments in protocols that are less labour intensive are necessary. This study examines the use of insulin glargine for basal supplement in recovering critically ill patients. These patients represent a group who may benefit from such basal support therapy. In silico study results showed the potential in reducing nursing effort with the use of glargine. However, a protocol using only glargine for glucose control did not show to be effective in the simulated patients. This may be an indication that a protocol using only glargine is more suitable after discharge from critical care.

Keywords: hyperglycaemia, insulin glargine, tight glycaemic control, SPRINT, critical care

1. INTRODUCTION

Stress-induced hyperglycaemia is prevalent in critical care and can occur in patients with no history of diabetes (Capes et al., 2000; Van Den Berghe et al., 2001). Hyperglycaemia worsens outcomes, increasing the risk of severe infection (Bistrian, 2001), myocardial infarction (McCown et al., 2000) and critical illnesses such as polyneuropathy and multiple organ failure.

A number of studies have investigated the effects on patient outcomes when blood glucose levels are controlled with insulin, and revealed markedly positive results. The most notable is a study by Van Den Berghe et al. (2001) that showed tightly controlled glucose levels averaging 6.1mmol/L reduced cardiac intensive care unit (ICU) patient mortality by 18-45%. The use of intravenous (IV) insulin therapy in ICU patients to lower hyperglycaemia, whether or not a patient is a diagnosed diabetic, became the focus of much discussion following this landmark study. Krinsley (2004) showed a 17-29% reduction in mortality over a wider ICU population with a higher blood glucose average of 7.75mmol/L. Finally, the SPRINT protocol reduced mortality 36-47% with a more critically ill cohort (Chase et al., 2008a).

SPRINT or Specialised Relative Insulin Nutrition Tables protocol (Chase et al., 2008a) is a simple wheeled-based system that modulates insulin and nutritional inputs for tight glycaemic control. SPRINT uses the absolute blood glucose level, change in blood glucose level, and current insulin and nutrition administration rates to identify effectively the patient’s insulin sensitivity and respond accordingly. The unique wheel-based designed of SPRINT allows all of these metrics to be incorporated into an essentially nurse-automated protocol.

While many ICU patients are benefiting from tight blood glucose control (TGC), moderate to high levels of hypoglycaemia are still tolerated within less acute wards. The use and benefits of insulin protocols within these units have not yet been widely addressed in the literature (Whitehorn, 2007). The management of glycaemic levels in these units remains under the influence of ineffective standard characterized by a tolerance for hyperglycaemia and a reluctance to use insulin intensively.

Based on current evidence from studies in medical and surgical ICUs, it is logical to expect that the maintenance of normoglycaemia within less acute ward patients would limit potential complications associated with elevated blood glucose levels. This assumption is not unreasonable as patients in the ICU and less acute wards share an accelerated catabolic, hyperglycaemic state that also reduces the immune response. Extending tight control to these wards could minimise rebound hyperglycaemia on discharge to the wards (Goldberg et al., 2004) and minimize the development of (new) infections, thus improving overall patient care.

However, to fully implement TGC in less acute wards pose a challenge as these wards do not have the same nursing
resources compared to ICU, making constant monitoring and titration difficult. Hence, there is a pressing need for insulin delivery protocols that can be successfully implemented with minimal clinical effort and resources.

This study uses an integrated pharmacokinetics/dynamics model of insulin glargine, intravenous insulin and glucose from Wong et al. (2008a, b) and Lin et al. (2010) to simulate less intensive TGC protocols using insulin glargine for provision of basal insulin. A retrospective cohort consisting of 10 metabolically stable patients were selected from a cohort of ICU patient receiving TGC with the SPRINT protocol (Chase et al., 2008a). These patients represent a group that may benefit from less intensive protocols that uses insulin glargine as basal supplement. Effective use of insulin glargine, commonly injected once or twice a day, promises a potential to reduce nursing workload, which has added benefits (Chase et al., 2008b). Effective protocols indicated by positive simulation results can then be considered for a clinical pilot study, moving one step closer to providing TGC in the less acute wards.

2. SYSTEM MODEL

The pharmacodynamic model used in this study integrates an insulin glargine compartmental model from Wong et al. (2008a, b) and a generic insulin-glucose model, ICING, from Lin et al. (2010). The glargine model has been validated against literature results (Wong et al., 2008a, b) and the model ICING from Lin et al. (2010) has been clinically validated in data from critically ill patients. The integrated model in this study is defined:

**Insulin Glargine Compartmental Model**

Precipitate State:

\[
p_{\text{gla}} = \frac{-k_{\text{prep,gla}}(t)p_{\text{gla}}(t)}{1 + k_{\text{prep,gla}}(t)\tau_{\text{dis, max}} p_{\text{gla}}(t)} + u_{p,\text{gla}}(t) \tag{1}
\]

Hexameric State:

\[
x_{h,\text{gla}} = -(k_{1,\text{gla}} + k_d)x_{h,\text{gla}}(t) - \frac{-k_{\text{prep,gla}}(t)p_{\text{gla}}(t)}{1 + k_{\text{prep,gla}}(t)\tau_{\text{dis, max}} p_{\text{gla}}(t)} + u_{h,\text{gla}}(t) \tag{2}
\]

Dimeric/Monomeric State:

\[
x_{\text{dm}} = -(k_2 + k_{\text{dm}})x_{\text{dm}}(t) + k_{1,\text{gla}}x_{h,\text{gla}}(t) + u_{m,\text{gla}}(t) \tag{3}
\]

Interstitial:

\[
x_i = k_2x_{\text{dm}}(t) - (k_{di} + k_3)x_i(t) \tag{4}
\]

where all the variables in Equation (1)–(4) are defined in Table 1.

**Glucose-Insulin Physiology Model**

\[
\dot{G} = -p_{\text{g}}G(t) - S_I(t) + \frac{Q(t)}{V_G} + P(t) + EG_P - CNS \tag{5}
\]

\[
\dot{I} = -n_K I(t) - \frac{n_L I(t)}{1 + \alpha _{G} Q(t)} - n_l I(t) - Q(t) + \frac{u_{en}(t)}{V_I} + (1 - x_L) \frac{u_{en}}{V_I} \tag{6}
\]

\[
\dot{P}_1 = -d_1 P_1 + D(t) \tag{7}
\]

\[
\dot{P}_2 = -\min (d_2 P_2, P_{\text{max}}) + d_1 P_1 \tag{8}
\]

\[
P(t) = \min (d_2 P_2, P_{\text{max}}) + P N(t) \tag{9}
\]

\[
u_{en}(t) = k_1 e^{-\frac{t_{en}^2}{3s^2}} \text{ when C-peptide data are not available} \tag{10}
\]

where all the variables in Equations (5)–(11) are defined in Table 2.

3. METHOD

The effectiveness of glargine for blood glucose control is assessed in silico. Patient data were selected retrospectively for the simulation study from a cohort of patients who received insulin therapy under the SPRINT protocol during their stay in the Christchurch Hospital ICU (Chase et al., 2008a). SPRINT uses insulin boluses and modulates feed rate hourly to maintain blood glucose levels within a desirable range of 4.0–6.1 mmol/L. It takes into account of a particular patient’s apparent insulin sensitivity at any given time to determine the insulin bolus size and feed rate.

The use of glargine is intended for patients who are recovering from their critical illness, and hemostability had been regained. The patients selected for simulation are those who exhibit metabolic stability within 30 hour of ICU admission. Metabolic stability in patients in terms of stable blood glucose-insulin response is defined by:

- Hourly insulin boluses \( \leq 3U \) for at least 12 hours.
- Hourly feed rate of \( \geq 60\% \) of individual patient’s goal feed rate.

| \( x_{h,\text{gla}}(t) \) | Mass in glargine hexameric compt. \( \text{[mU]} \) |
| \( p_{\text{gla}}(t) \) | Mass in glargine precipitate compt. \( \text{[mU]} \) |
| \( x_{\text{dm}}(t) \) | Mass in dimer monomer compartment \( \text{[mU]} \) |
| \( x_i(t) \) | Mass in the interstitium compt. \( \text{[mU]} \) |
| \( \tau_{\text{dis, max}} \) | Max glargine precip. dissolution rate \( \text{[min/U]} \) |
| \( u_{\text{total, gla}}(t) \) | Insulin glargine input \( \text{[mU/min]} \) |
| \( u_{p,\text{gla}}(t) \) | Glargine precip. state insulin input \( \text{[mU/min]} \) |
| \( u_{h,\text{gla}}(t) \) | Glargine hexamer state insulin input \( \text{[mU/min]} \) |
| \( u_{m,\text{gla}} \) | Glargine dimer/monomer state insulin input \( \text{[mU/min]} \) |

Table 1. Nomenclature for the Insulin glargine compartmental model
Ten patients were chosen from the entire SPRINT cohort (Chase et al., 2008a). Males make up 70% of the patients. The SPRINT protocol is carried out in 60 patients who are assigned into two groups. The differences of blood glucose levels are compared to clinical data for the goodness of control, amount of insulin and feed given, and nursing effort intensity. Specifically, nursing effort intensity is measured by the number of intervention required, which includes measuring blood glucose levels, adjusting feed rates, giving SPRINT IV insulin boluses, and giving glargine boluses. The frequencies of blood glucose measurements, changes in feed rates and IV insulin boluses are governed by the SPRINT protocol (Chase et al., 2008a). In particular, blood glucose levels are measured hourly unless 3 hourly measurements have been taken within 4–6.1 mmol/L. In which case, measurement frequency is changed to 2 hourly until blood glucose levels fail to stay in the 4–6.1 mmol/L band.

Four different protocols involving the use of glargine are tested to evaluate their potentials for a clinical pilot study. Table 3 lists the full descriptions of simulation protocols that are carried out in this study.

<table>
<thead>
<tr>
<th>Protocol</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical records</td>
<td>Clinical data from Chase et al. (2008a)</td>
</tr>
<tr>
<td>SPRINT</td>
<td>Simulation of the protocol SPRINT</td>
</tr>
<tr>
<td>SPRINT+Glargine</td>
<td>Simulation of SPRINT protocol with insulin glargine as a basal insulin replacement therapy</td>
</tr>
<tr>
<td>SPRINT-1U+Glargine</td>
<td>Simulation of SPRINT protocol with insulin glargine where the boluses calculated using SPRINT are reduced by 1U</td>
</tr>
<tr>
<td>SPRINT-2U+Glargine</td>
<td>Simulation of SPRINT protocol with insulin glargine where the boluses calculated using SPRINT are reduced by 2U</td>
</tr>
<tr>
<td>Glargine Only</td>
<td>Simulation of daily glargine IV insulin boluses from SPRINT</td>
</tr>
</tbody>
</table>

The dosing frequency of glargine is 24 hours, where the first dose is given at 12 hours after ICU admission. The size of the initial glargine bolus is the sum of SPRINT insulin boluses administered during the previous 12 hours. The following glargine boluses are calculated as being half of the total daily insulin (IV boluses + glargine) from the previous day. Each bolus is capped at 40U for safety against hypoglycaemia, except when glargine is simulated without the use of SPRINT. In the case where only glargine is used for blood glucose control, a cap of 72 U/day is used. In addition, clinical records of feed rates are used in the simulations without SPRINT.

### 4. RESULTS

A summary of the results for all 10 patients is shown in Table 4. The blood glucose levels from simulation results of SPRINT are very similar to clinical records, confirming the validity of the virtual trial method. The range in feed for SPRINT is much tighter than clinical records. This can be expected as feed rate is often turned off for patients in real life during various medical procedures. The simulation of SPRINT however does not let the feed rate drop to below 30% of an individual’s goal feed rate.

In the simulations of SPRINT+Glargine, a lot more insulin in total is used even though the amount of IV bolus from SPRINT has decreased. The amount of IV insulin bolus used in SPRINT+Glargine protocol is 15% less than SPRINT, and 10% less than clinical records. The control in blood glucose levels (BG) is still good, with a median 75% [IQR: 69.5–80.4%] time in 4.0–6.1 mmol/L
glycaemic band. Feed rate is comparable to SPRINT, however the upper quartile is significantly higher. This is because patients are still given similar amount of insulin towards their end of ICU stay, resulting in patients being able to receive a lot more feed during this time. The most noticeable difference in SPRINT+Glargine compared to SPRINT and clinical records is the reduction in nursing effort, expressed in intervention frequency.

When SPRINT is reduced by 1 and 2 U while glargine is given daily, the tightness of BG is reduced as well as the total amount of insulin used. The amount of feed is also reduced for these two protocols. Because of the loss in tightness of control, intervention frequency is actually not reduced with the use of glargine in these simulations.

The percentage of time spent within desired band reduced to only 14.4% in the simulation using Glargine only. The daily glargine amount just meet the patient’s requirements when comparing to the total amount of insulin used clinically. As glargine is known to have a slow build up, and can take 3 days or more to reach a steady plasma insulin level (Lehmann et al., 2009), the significant decrease in time in band is not a surprise. Finally, all protocols are safe with respect to hypoglycaemia.

Clinical records and simulation results of SPRINT+Glargine on patient 5122 are shown in Figure 1. The top panel of each subfigure shows the blood glucose levels (BG) through time. BG is well controlled with median and IQR of 5.25 [4.97, 5.59] mmol/L and 5.14 [4.82, 5.82] mmol/L for clinical and SPRINT+Glargine respectively. The percentages of time spent within 4.0–6.1 mmol/L band (%), 4.0–6.1 mmol/L < 2.2 mmol/L band [%] are shown in Table 4. The simulation results from SPRINT are very similar to clinical records. Therefore the virtual patient simulation method is a realistic way to assess different TGC protocols. The simulations of SPRINT+Glargine in this study shows glargine can be used successfully in patients who are insulin resistant but metabolically stable. The extra requirement for TGC is stable. These patients constitute a group who require a stable, constant “uplift” in their insulin production during their illnesses. The extra requirement may be due to temporary insulin resistance, brought on by excess catecholamines during illness (Bistrain, 2001; McCowen et al., 2000), or temporary impaired endogenous insulin production.

The simulation results from SPRINT are very similar to clinical records. Therefore the virtual patient simulation method is a realistic way to assess different TGC protocols. The simulations of SPRINT+Glargine in this study shows glargine can be used successfully in patients who are insulin resistant but metabolically stable. The extra requirement for TGC is stable. These patients constitute a group who require a stable, constant “uplift” in their insulin production during their illnesses. The extra requirement may be due to temporary insulin resistance, brought on by excess catecholamines during illness (Bistrain, 2001; McCowen et al., 2000), or temporary impaired endogenous insulin production.

The simulation results from SPRINT are very similar to clinical records. Therefore the virtual patient simulation method is a realistic way to assess different TGC protocols. The simulations of SPRINT+Glargine in this study shows glargine can be used successfully in patients who are insulin resistant but metabolically stable. The extra requirement for TGC is stable. These patients constitute a group who require a stable, constant “uplift” in their insulin production during their illnesses. The extra requirement may be due to temporary insulin resistance, brought on by excess catecholamines during illness (Bistrain, 2001; McCowen et al., 2000), or temporary impaired endogenous insulin production.

By reducing the amount of bolus in SPRINT by 1 U while still maintaining insulin glargine (SPRINT−1U+Glargine), the results in terms of BG level are still comparable to clinical records. However, the simulations of SPRINT−2U+Glargine and Glargine Only are not sufficient to provide effective glycaemic management for these patients even though the total insulin used is comparable to clinical data. This could be explained by the slow build up of insulin glargine which could take 3 days or longer (Lehmann et al., 2009; Heise et al., 2002).
adaptation of glargine. Even though the patients selected for this study are reasonably stable, critically ill patients in general appear to require more rigorous insulin therapy than using long term insulin supplement such as glargine. This indicates a protocol using glargine only is perhaps only suitable for the less acute wards. However, an early, smooth transition from IV insulin to a combination may help by reducing undesirable variations in blood glucose levels (Egi et al., 2006).

The use of glargine is very conservative in this study, being less than or equal to half of the daily insulin requirement from the previous day. This is to address the course of recovery for patients where they are expected to slowly regain normal insulin sensitivity or basal insulin production.

The protocol SPRINT did not seem to be sensitive to glargine supplementing a patient’s insulin requirement. This may be due to the design of SPRINT aiming to achieve a steady state of 3U insulin and 60% of feed in patients. In addition, due to the fact that SPRINT is designed in the format of look-up tables, its adjustments in insulin and feed are rather discretized. By reducing SPRINT insulin by 1U while glargine is given to patients in simulations, the control in blood glucose levels is not compromised. This protocol, with further investigation and revision, may have the potential of being employed in a clinical pilot study. A clinical pilot study will provide valuable information on the practicality and clinical benefit of glargine in stable ICU patient. This will be the first step towards designing glycaemic control protocols for patient in the less acute wards. After all, SPRINT has been proven to provide safe TGC and gained considerable trust in Christchurch Hospital ICU where it is first implemented. A clinical pilot study incorporating SPRINT will be significantly easier to deploy compared to a protocol without it.

Finally, this study only included 10 patients, therefore its results are only a positive “proof-of-concept”, and not conclusive. However, the use of glargine is shown to supplement a patient’s basal insulin requirement and has the potential to reduce nursing effort. Further reduction in nursing effort without compromising tight control may be possible by revising the blood glucose measurement frequency (3 to 4 hourly) while patients are receiving glargine.

6. CONCLUSION

This study investigated the use of glargine as basal insulin support in stable, recovering ICU patients. A validated insulin glargine compartmental kinetics model and an insulin-glucose pharmacodynamic model are used to perform simulation of protocols using glargine. Ten metabolically stable patients who received insulin therapy under SPRINT protocol during their stay in Christchurch Hospital ICU were selected for in-silico assessments. Protocols using daily injection of glargine reduced nursing effort provided blood glucose levels are largely maintained within a desirable range. A protocol using glargine only for glucose control did not show to be effective in the patients studied. This may be an indication that a protocol using glargine only is more suitable for the less acute wards. However, an early, smooth transition from IV insulin to a combination may help by reducing undesirable variations in blood glucose levels. Finally, the use of glargine is shown to supplement a patient’s basal insulin requirement without the risk of hypoglycaemia.
REFERENCES


